Mostrar el registro sencillo del documento
Therapeutic efficacy of Pudilan Xiaoyan Oral Liquid (PDL) for COVID-19 in vitro and in vivo
| dc.creator | Deng, Wei | |
| dc.creator | Xu, Yanfeng | |
| dc.creator | Kong, Qi | |
| dc.creator | Xue, Jing | |
| dc.creator | Yu, Pin | |
| dc.creator | Liu, Jiangning | |
| dc.creator | Lv, Qi | |
| dc.creator | Li, Fengdi | |
| dc.creator | Wei, Qiang | |
| dc.creator | Bao, Linlin | |
| dc.date.accessioned | 2020-09-04T14:28:49Z | |
| dc.date.available | 2020-09-04T14:28:49Z | |
| dc.date.created | 2020-05-08 | |
| dc.identifier.issn | 2059-3635 | spa |
| dc.identifier.other | https://www.nature.com/articles/s41392-020-0176-0 | spa |
| dc.identifier.uri | http://hdl.handle.net/20.500.12010/12694 | |
| dc.format.extent | 3 páginas | spa |
| dc.format.mimetype | application/pdf | spa |
| dc.language.iso | eng | spa |
| dc.publisher | signal transduction and targeted therapy | spa |
| dc.source | reponame:Expeditio Repositorio Institucional UJTL | spa |
| dc.source | instname:Universidad de Bogotá Jorge Tadeo Lozano | spa |
| dc.subject | Pudilan Xiaoyan Oral Liquid (PDL) | spa |
| dc.subject | COVID-19 in vitro and in vivo | spa |
| dc.title | Therapeutic efficacy of Pudilan Xiaoyan Oral Liquid (PDL) for COVID-19 in vitro and in vivo | spa |
| dc.type.local | Artículo | spa |
| dc.subject.lemb | Síndrome respiratorio agudo grave | spa |
| dc.subject.lemb | COVID-19 | spa |
| dc.subject.lemb | SARS-CoV-2 | spa |
| dc.subject.lemb | Coronavirus | spa |
| dc.rights.accessrights | info:eu-repo/semantics/restrictedAccess | spa |
| dc.type.hasversion | info:eu-repo/semantics/acceptedVersion | spa |
| dc.rights.local | Acceso restringido | spa |
| dc.identifier.doi | https://doi.org/10.1038/s41392-020-0176-0 | spa |
| dc.description.abstractenglish | Dear Editor, Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), has rapidly swept through the worldwide, with more than 3 million confirmed cases. Until now, no vaccine or effective therapeutic measures are provided to prevent the SARS-CoV-2 infection. Existing medicines have some strong advantages on pharmacokinetics, known side effects, safety and dosing regimens.1 Although remdesivir and chloroquine could effectively inhibit the replication of SARS-CoV-2 in vitro,2 no medicine candidates have been evaluated in vivo by using animal models with SARS-CoV-2 infection. | spa |
| dc.type.coar | http://purl.org/coar/resource_type/c_6501 | spa |
